FULCRUM THERAPEUTICS INC. - COMMON STOCK

Fulcrum Therapeutics to Participate in Upcoming September Conferences

27 Aug 2024 13:05:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

23 Aug 2024 13:30:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer

19 Aug 2024 04:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09 Aug 2024 13:30:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024

31 Jul 2024 04:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET

24 Jul 2024 05:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress

12 Jun 2024 05:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference

06 Jun 2024 05:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024

13 May 2024 04:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy

13 May 2024 03:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate in Upcoming May Conferences

09 May 2024 05:00:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology

08 May 2024 05:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET

06 May 2024 05:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium

28 Mar 2024 13:05:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

22 Mar 2024 13:30:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer

18 Mar 2024 04:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

08 Mar 2024 13:30:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference

05 Mar 2024 05:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023

27 Feb 2024 04:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET

20 Feb 2024 13:01:00 By Nasdaq GlobeNewswire